Lantern Pharma Reports Promising Preclinical Results for LP-184 in Rare Pediatric Brain Cancer

Lantern Pharma (NASDAQ: LTRN) has reported strong preclinical results for its drug candidate LP-184 in treating atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive form of pediatric brain cancer. The data, presented by Dr. Eric Raabe of Johns Hopkins at the Society for Neuro-Oncology's Pediatric Neuro-Oncology Conference, showed that LP-184 significantly improved survival in two mouse models of ATRT. One model demonstrated a remarkable 345% increase in median survival, from 20 to 89 days, with statistical significance (p<0.0001).

The implications of these findings are substantial for pediatric oncology, as ATRT is driven by SMARCB1 gene inactivation and currently lacks effective, low-toxicity treatments. LP-184 demonstrated potent anti-tumor activity across multiple ATRT subtypes, high blood-brain barrier penetration, and a favorable safety profile in preclinical studies. These characteristics are particularly important for pediatric brain cancers, where effective treatments must balance efficacy with minimal long-term side effects for developing patients.

Lantern Pharma plans to launch a pediatric Phase I clinical trial in late 2025 or early 2026, following the completion of its ongoing adult trial and pending necessary consortium approvals. The company's approach to drug development leverages artificial intelligence through its proprietary RADR® platform, which utilizes over 200 billion oncology-focused data points. More information about the company's innovative approach can be found at https://www.lanternpharma.com/.

The successful development of LP-184 could address a significant unmet medical need in pediatric oncology. ATRT primarily affects young children and has a poor prognosis with current treatment approaches, which often involve aggressive combinations of surgery, radiation, and chemotherapy. The potential for a targeted therapy with demonstrated blood-brain barrier penetration represents a crucial advancement in treating this devastating disease. The full press release detailing these findings is available at https://ibn.fm/uOUKi.

These preclinical results reinforce LP-184's potential as a novel therapy for ATRT and highlight the growing importance of AI-driven drug discovery in addressing complex medical challenges. The transition from promising preclinical data to clinical trials represents a critical step in bringing potentially life-changing therapies to pediatric cancer patients who currently have limited treatment options.